A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.

This study is looking for people with advanced cancer that has a specific change in their BRAF gene. All participants must have already tried other treatments for their cancer, and those treatments are no longer working well enough.

For certain types of cancer, like melanoma or bowel cancer, you might need to have received specific treatments before joining. For example, if you have melanoma, you must have tried medicines that target the BRAF V600 gene and other immune-boosting treatments. If you have bowel cancer, you might need to have had certain chemotherapy treatments.

You cannot join the study if your brain tumours are larger than 4 cm, if you are currently on other cancer treatments, or if you have certain eye conditions or muscle disorders. The study is open to both men and women, aged 16 and older.

If you join this study, you will take the study medicine, PF-07799933, as a tablet twice a day. Depending on your cancer, you might also receive other study medicines. For example, if you have melanoma, you might also take binimetinib tablets twice a day. If you have bowel cancer, you might receive cetuximab as an injection into a vein, either weekly or every two weeks in the clinic. Additionally, some people with bowel cancer might also receive a chemotherapy treatment called mFOLFOX6.

You could be taking these study medicines for up to two years. Throughout this time, you will have regular visits to the clinic so the study team can monitor your health, how you're reacting to the treatments, and how well the treatment is working. These visits will help ensure your safety and gather important information for the study.